In this installment of the FLASCO OncoPod, we explore the critical role of Minimal Residual Disease (MRD) testing in advancing cancer care with Dr. Ivan Borrello, a distinguished oncologist from Tampa General Hospital.

Dr. Borrello dives into the science behind MRD testing, its applications in hematologic malignancies, and how it informs treatment decisions and long-term patient outcomes. Gain expert insights on the latest advancements in MRD technology and its impact on precision medicine in oncology.

Join us for an enlightening conversation designed for oncology professionals dedicated to staying at the forefront of cancer diagnostics and care.